Eisai (MUN:EII0) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

EII0 Overzicht aandelen

Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.

Over het bedrijf

EII0 fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	4/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	4/6

Beloningen

Risicoanalyse

Eisai Co., Ltd. Concurrenten

Merck KGaA

XTRA:MRK

€65.7b

Dermapharm Holding

XTRA:DMP

€1.6b

PharmaSGP Holding

XTRA:PSG

€299.8m

Sartorius

XTRA:SRT3

€14.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Eisai
Historische aandelenkoersen
Huidige aandelenkoers	JP¥54.17
52 Week Hoogtepunt	JP¥70.86
52 Week Laag	JP¥36.61
Bèta	0.17
11 maand verandering	-5.31%
3 maanden verandering	-20.01%
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	34.52%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	EII0	DE Pharmaceuticals	DE Markt
7D	0%	-4.1%	-1.0%
1Y	n/a	-11.4%	16.1%

Prijsvolatiliteit

Is EII0's price volatile compared to industry and market?
EII0 volatility
EII0 Average Weekly Movement	4.6%
Pharmaceuticals Industry Average Movement	7.7%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.5%

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1941	11,322	Haruo Naito	www.eisai.co.jp

Eisai Co., Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Eisai zich tot de beurswaarde?
EII0 fundamentele statistieken
Marktkapitalisatie	€14.46b
Inkomsten(TTM)	€183.92m
Inkomsten(TTM)	€5.08b

78.6x

Koers/Winstverhouding

2.8x

P/S-verhouding

Is EII0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
EII0 resultatenrekening (TTM)
Inkomsten	JP¥737.10b
Kosten van inkomsten	JP¥190.01b
Brutowinst	JP¥547.09b
Overige uitgaven	JP¥520.38b
Inkomsten	JP¥26.71b

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	93.12
Brutomarge	74.22%
Nettowinstmarge	3.62%
Schuld/Eigen Vermogen Verhouding	18.8%

Hoe presteerde EII0 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.2%

Huidig dividendrendement

86%

Uitbetalingsratio

This company listing is no longer active

EII0 Overzicht aandelen

Beloningen

Risicoanalyse

Eisai Co., Ltd. Concurrenten

XTRA:MRK

€65.7b

XTRA:DMP

€1.6b

XTRA:PSG

€299.8m

XTRA:SRT3

€14.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Recent updates

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference

Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting

DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022

Eisai Presents New Data for Lecanemab (Ban2401) At Alzheimer's Association International Conference

Merck & Co., Inc. and Eisai Co., Ltd. Provides Update on Phase 3 LEAP-002 Trial

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Eisai Co., Ltd. Samenvatting

78.6x

2.8x

Inkomsten en omzet

Dividenden

2.2%

86%